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Background: Rotavirus (RV) is the commonest cause of acute gastroenteritis in infants and young children worldwide.
A Quality of Life study was conducted in primary care in three European countries as part of a larger epidemiological
study (SPRIK) to investigate the impact of paediatric rotavirus gastroenteritis (RVGE) on affected children and their
parents.
Methods: A self-administered questionnaire was linguistically validated in Spanish, Italian and Polish. The questionnaire
was included in an observational multicentre prospective study of 302 children aged <5 years presenting to a general
practitioner or paediatrician for RVGE at centres in Spain, Italy or Poland. RV infection was confirmed by polymerase
chain reaction (PCR) testing (n= 264). The questionnaire was validated and used to assess the emotional impact of
paediatric RVGE on the parents.
Results: Questionnaire responses showed that acute RVGE in a child adversely affects the parents’ daily life as well as
the child. Parents of children with RVGE experience worry, distress and impact on their daily activities. RVGE of greater
clinical severity (assessed by the Vesikari scale) was associated with higher parental worries due to symptoms and
greater changes in the child’s behaviour, and a trend to higher impact on parents’ daily activities and higher parental
distress, together with a higher score on the symptom severity scale of the questionnaire.
Conclusions: Parents of a child with acute RVGE presenting to primary care experience worry, distress and disruptions
to daily life as a result of the child’s illness. Prevention of this disease through prophylactic vaccination will improve the
daily lives of parents and children.
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Rotavirus infection is the leading cause of acute gastro-
enteritis in infants and young children worldwide [1], and
is estimated to cause over 146,000 hospital admissions per
year in children aged <5 years in the World Health
Organization (WHO) European region [2]. In the 23.6
million children aged <5 years in the European Union* Correspondence: diez_jav@gva.es
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distribution, and reproduction in any medium(EU) countries, 3.6 million episodes of rotavirus illness are
estimated to occur annually, resulting in almost 700,000
outpatient visits, over 87,000 hospitalisations and 231
deaths per year [3].
Vaccination against rotavirus is recommended in guide-
lines issued by the European Society for Paediatric Infec-
tious Diseases and European Society for Paediatric
Gastroenterology, Hepatology, and Nutrition [4,5], and by
the WHO Strategic Advisory Group of Experts [6]. Two
rotavirus vaccines have demonstrated good clinical efficacy
and safety in large clinical trials and are currently available
in Europe, a two-dose live attenuated monovalent humanCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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three-dose live human-bovine reassortant vaccine (Sanofi
Pasteur MSD) [9].
Rotavirus gastroenteritis is associated more frequently
with severe symptoms and increased hospital admissions,
compared with acute gastroenteritis due to other infec-
tious causes [10]. The severity of symptoms may cause
worry, anxiety and distress in the affected child’s parents,
as well as distress to the child. Family life may also be dis-
rupted, for example if parents have to take time away from
work to look after a child with rotavirus gastroenteritis or
to travel to healthcare facilities, or if parents’ other daily
activities are curtailed. Information about the emotional
impact of rotavirus gastroenteritis on the family is import-
ant for a fuller understanding of the burden of rotavirus
disease. We conducted a quality of life study as part of the
Surveillance for Practitioner/Paediatrician for Rotavirus
Infections in Kids (SPRIK) epidemiological study asses-
sing the disease burden of rotavirus among children seen
by primary care physicians, to investigate the impact of a
child’s rotavirus gastroenteritis on the quality of life of par-
ents and children in three European countries, namely
Spain, Italy and Poland. To our knowledge, this is the first
multicentre study to investigate this issue using the same
validated questionnaire in multiple countries.
Methods
Study design
This analysis was conducted as part of the Surveillance for
Practitioner/Paediatrician for Rotavirus Infections in Kids
(SPRIK) study. The main SPRIK study was an observa-
tional prospective multicentre study assessing the burden
of rotavirus infections in children presenting to general
practitioners or paediatricians in six European countries,
and has been fully published elsewhere [11]. Children aged
less than 5 years were eligible for the study if they pre-
sented to participating general practitioners or paediatri-
cians with acute rotavirus gastroenteritis (rotavirus-
positive stool sample) and their parent/guardian gave writ-
ten informed consent. Acute rotavirus gastroenteritis was
defined as diarrhoea for less than 14 days, with or without
vomiting. Diarrhoea was defined as three or more looser
than normal stools within a 24-hour period. Stool samples
were initially tested for rotavirus by the general practi-
tioner or paediatrician using a rapid immunochromato-
graphic test kit (RotaStripW, Coris BioConcept, Gembloux,
Belgium) at the initial visit or within 4 days. Rotavirus-
positive samples were confirmed and characterised by
polymerase chain reaction (PCR) testing at a central refer-
ence laboratory (Health Protection Agency laboratory,
London, UK) using published oligonucleotide primers and
methods [12,13]. As all cases enrolled in the study were
RotaStripW-positive, the study did not have a rotavirus-
negative control group, although PCR-negative cases wereanalysed as a comparison with the PCR-positive cases.
The clinical severity of rotavirus gastroenteritis was cate-
gorised according to the Vesikari score [14]. As testing for
rotavirus infection was not part of routine clinical practice,
it was not possible to determine whether patients enrolled
in the study had a previous history of rotavirus gastro-
enteritis. The study was carried out before widespread
introduction of rotavirus vaccines, and therefore few if any
children in the study population had received rotavirus
vaccination.
The study was conducted in accordance with the Dec-
laration of Helsinki and Good Clinical Practice guidelines.
The protocol was reviewed and approved by the local in-
dependent ethics committee or institutional review board
for each participating general practitioner/paediatrician
network (Italy: Independent Ethics Committee for the
Assessment of Clinical trials on Drugs of Local Healthcare
Authority No. 8, Asolo; Spain: Primary Health-Care Clin-
ical Review Board for Valencia and Castellón, Valencia;
Poland: Bioethics Committee, Regional Medical Chamber,
Kielce).
The present study on quality of life was conducted
among SPRIK participants enrolled at centres in Spain,
Poland and Italy. Parents or caregivers of the enrolled chil-
dren were interviewed about their child’s symptoms, and
at the end of the study visit a copy of a self-administered
questionnaire was given to the parent of each enrolled pa-
tient. Parents were asked to complete the questionnaire at
home within seven days of the clinic visit and to return
the completed questionnaire using a prepaid envelope or
by handing it to their paediatrician. During a follow-up
phone call or visit, a study nurse checked whether the
questionnaire had been completed and returned, and
reminded the parents to return it if they had not already
done so.
The questionnaire was developed from an initial 54-item
pilot questionnaire, linguistically validated in Spanish, Pol-
ish and Italian. After multitrait analysis and item reduc-
tion, the final questionnaire consisted of 44 items in five
scales, Symptom Severity (13 items); Child’s Behaviour (6
items); Parents’ Worries due to Symptoms (8 items); Par-
ents’ Distress (7 items); and Impact on Parents’ Daily Ac-
tivities (10 items). The questionnaire was validated by
assessing internal consistency reliability, floor and ceiling
effects and scale-scale correlations, as described in
Additional file 1 and presented at the International Society
for Pharmacoeconomics and Outcomes Research (ISPOR)
congress in 2008 [15].Statistical analysis
Analyses of the scores were carried out on data from the
cohort of patients with a rotavirus-positive PCR test. De-
scriptive statistics including frequency, mean, and
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tative variables. For qualitative variables, number and per-
centage were recorded, with missing data included in the
calculation of percentages. Non-parametric or ordinal
variables were compared using the Mann–Whitney-
Wilcoxon test when comparing two groups, or the
Kruskal-Wallis test when comparing three or more
groups. All data processing was performed using SAS
for Windows (Statistical Analysis System, Version 9).
Results
Demographic and clinical characteristics of the study
population
Questionnaires were issued to the parents of all RotaS-
tripW-positive subjects, 426 in total, of whom 213 were
in Spain, 126 in Italy and 87 in Poland. Subjects were
enrolled at 15 participating centres in Spain, 12 in Italy
and 15 in Poland. A total of 302 respondents returned
the questionnaire with at least one item completed, 190
in Spain, 37 in Italy and 75 in Poland. The response rate
was 302/426 (71%) overall, 190/213 (89%) in Spain, 75/
87 (86%) in Poland, and 37/126 (29%) in Italy. Of the
302 questionnaires returned, the majority of cases (87%,
n = 264) were rotavirus-positive on the PCR test, and
11% (n = 34) were rotavirus-negative on PCR. PCR
results were missing in 4 cases.
Questionnaires from parents of children with PCR-
confirmed rotavirus gastroenteritis were included in the
main analysis (n = 264). Demographic and clinical char-
acteristics for this population are presented in Table 1.
The sex ratio was balanced between male and female
subjects (n = 135 and n = 129, respectively). One hundred
and seventy-one parents (65%) were Spanish, 67 (25%)
were Polish and 26 (10%) were Italian. The majority of
the patients (n = 199, 75%) had no underlying major
medical history. A total of 84 patients (32%) had
attended a day-care centre and 9 patients (3%) had been
admitted to a hospital in the 14 days prior to the visit.
Clinical symptoms were categorised as mild on the Vesi-
kari scale in 70 patients (27%), moderate in 137 (52%)
and severe in 57 (22%) (Table 1).
A further 34 questionnaires were received from par-
ents of children who were rotavirus-negative on PCR
testing. PCR results were missing in 4 cases.
Questionnaire validation
Of the 302 questionnaires returned (n= 264 PCR-positive,
n = 34 PCR-negative, n = 4 PCR results missing), 291 ques-
tionnaires provided sufficient data for inclusion in the ana-
lysis of psychometric properties. Item convergent and
discriminant validity was good, no strong floor or ceiling
effects were observed, internal consistency reliability was
high, and scale–scale correlations indicated a strong rela-
tionship between all the scales showing consistency but noredundancy. The validation results are presented in more
detail in Additional file 1.Impact of rotavirus gastroenteritis on children and their
parents
The Symptom Severity, Parents’ Worries due to Symptoms
and Child’s Behaviour scales all showed statistically signifi-
cant differences across age groups, although the pattern
varied by scale (Figure 1a). The Symptom Severity
(p< 0.001) and Parents’ Worries due to Symptoms
(p< 0.01) scores both increased with the child’s age up to
35 months and then declined (Figure 1a). The Child’s Be-
haviour score (p< 0.01) was lowest for children aged up to
6 months and highest in children aged 12–23 months, then
progressively declined with age. Parents of children aged up
to 6 months reported less impact on their daily activities
than parents of children in the other age groups, though
the difference did not reach statistical significance (p> 0.1).
There were no statistically significant differences in the
scores between boys and girls on any of the five scales
(p> 0.1 for Symptom Severity, Parents’ Worries due to
Symptoms, Child’s Behaviour, and Impact on Parents’ Daily
Activities), although the Parents’ Distress score tended to
be higher for boys than for girls (p=0.0637).
Figure 1b shows the scores on each scale analysed by
country. Polish parents were more worried by the symp-
toms than parents from Spain and Italy (p< 0.001). Par-
ents from Poland also reported a more severe impact of
their child’s rotavirus gastroenteritis on their daily activ-
ities, compared with Spanish and Italian parents
(p< 0.01). There were no statistically significant differ-
ences between countries in the Symptom Severity, Child’s
Behaviour or Parents’ Distress scores. These findings sug-
gest that symptoms and behaviour as perceived by parents
were the same for all children, regardless of country, but
that the impact on the parents in terms of worry or dis-
ruption to daily activities varied by country.
Increasing severity of rotavirus gastroenteritis according
to the Vesikari score (Figure 1c) was associated with
higher parental worry due to symptoms (p< 0.001),
greater changes in the child’s behaviour (p< 0.05) and a
trend towards greater impact on the parents’ daily activ-
ities (p< 0.1) and higher parental distress (p< 0.1), as well
as a higher score on the symptom severity scale of the
questionnaire (p< 0.001).
Parents who had prior contact with a physician or a
medical facility due to the same rotavirus gastroenteritis
episode in their child had a higher Parents’ Distress score
than parents who had not (p< 0.05), although no statisti-
cally significant difference was observed in the other scales
of the questionnaire. No statistically significant differences
in the scores were observed between children with or
without a medical history, or between children who were
Table 1 Demographic and clinical characteristics of study
























Cardiac disease 6 2%
Pulmonary disease 31 12%
Immunodeficiency 1 <1%
Other disease 29 11%








14 days prior to enrolment
9 3%
Attending day-care 84 32%







Spain 47 (27%) 78 (46%) 46 (27%)
Poland 17 (25%) 44 (66%) 6 (9%)
Italy 6 (23%) 15 (58%) 5 (19%)
Total 70 (27%) 137 (52%) 57 (22%)
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those who were not (data not shown).
Figure 1d shows the scores on each scale for cases of
rotavirus gastroenteritis confirmed by PCR (n= 264), com-
pared with cases that tested negative for rotavirus by PCR
(n= 34). Rotavirus confirmed by PCR was associated with
significantly greater change in the child’s behaviour
(p< 0.05), parental distress (p< 0.01) and impact on the
parents’ daily activities (p< 0.05), compared with cases
with a negative PCR test (Figure 1d). There were no statis-
tically significant differences in the Symptom Severity or
Parents’ Worries due to Symptoms scores (Figure 1d).Discussion
In this paper we present results from a questionnaire
designed to be completed by parents to assess the impact of
childhood rotavirus gastroenteritis on affected children and
their parents as a quality of life measurement. The ques-
tionnaire was validated and used as part of a multinational
observational prospective study of children aged <5 years
presenting to a general practitioner or paediatrician for
acute rotavirus gastroenteritis. To our knowledge, this is
the first multicentre multinational study to investigate this
issue using the same validated questionnaire in a range of
different countries.
Two hundred and sixty-four children with PCR-confirmed
rotavirus infection were included in the main analysis. The
responses to the self-administered questionnaire showed
that PCR-confirmed rotavirus gastroenteritis was associated
with changes in the child’s behaviour, parental distress, par-
ental worry and impact on parents’ daily activities. This is
consistent with results from previous studies that have
found rotavirus gastroenteritis to be associated with particu-
larly severe symptoms [10] [16]. The validity of the question-
naire was supported by parents reporting a greater change
in their child’s behaviour and more worry due to symptoms
when the child had clinically severe rotavirus gastroenteritis
than when the child had clinically mild rotavirus gastro-
enteritis (as assessed by the Vesikari scale).
The five scales showed subtly different patterns of
variation in relation to demographic parameters. Parents’
perceptions of symptom severity and their worries due
to the symptoms unexpectedly increased with the child’s
age up to 35 months and then declined. Conversely, the
Child’s Behaviour score was lower for children aged
under 6 months than for the older age groups. This may
reflect the generally lower level of activity in children
aged under 6 months, which could make it more diffi-
cult to identify a change in behaviour compared with
older children. The impact on parents’ daily activities
showed a trend to lower scores in children aged under
6 months compared with the older age groups, possibly
because parents of children aged under 6 months are
likely to be on parental leave, or possibly because a child
aged under 6 months requires a great deal of parental at-
tention regardless of health status, and therefore the
change in response to illness may be correspondingly
less than in older age groups. Another possibility is that
parents of children aged under 6 months may be more
likely to visit hospitals or emergency rooms if the child
has acute severe rotavirus gastroenteritis symptoms, ra-
ther than presenting to general practice. As our study
was conducted in a general practice setting, it may thus
have tended to include less severe cases in very young
children, which in turn may have influenced parents’
assessments of the child’s behaviour and impact on the
parents’ daily activities.
Figure 1 Questionnaire scores in study subjects. Questionnaire scores in study subjects with PCR-confirmed rotavirus gastroenteritis (n = 264)
by (a) age group, (b) country and (c) severity of symptoms as assessed by Vesikari score. Questionnaire scores by rotavirus status as assessed by
polymerase chain reaction (PCR) in study subjects with PCR data (n = 298) (d). Mean score with standard error of the mean plotted as error bar.
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was associated with significantly greater change in the
child’s behaviour (p< 0.05), parental distress (p< 0.01)
and impact on the parents’ daily activities (p< 0.05),
compared with cases that initially tested positive on the
rapid test but were negative on PCR. The rapid test is
known to have a lower sensitivity than PCR testing (sen-
sitivity around 87%, specificity around 80% [GlaxoS-
mithKline Biologicals, unpublished data]). The relatively
low specificity would be expected to produce some false-
positive results (around 20%), and thus the RotaStripW
rapid test was used as a screen with positive results con-
firmed using PCR as a reference assay. Most of the cases
reported in this analysis (n = 264) were positive on both
PCR and the rapid test, and 34 cases that were initially
positive on the rapid test were negative on PCR (PCR
data were missing in 4 cases). The study was conducted
before widespread introduction of rotavirus vaccination,
and therefore represents the situation in an unvaccinated
population.
Parents in all three countries in the study perceived
similar changes in their child’s behaviour and similar
symptom severity, but there appeared to be subtle countryvariations in the parents’ perceptions of worry, distress or
disruption to daily activities. Polish parents reported
greater levels of worry due to their child’s symptoms and a
more severe impact on their daily activities compared with
Spanish or Italian parents, and there was a trend to greater
parents’ distress in Poland and Spain than in Italy. This
did not appear to be explained by differences in clinical se-
verity between countries, as Poland did not have a higher
percentage of severe cases than Spain or Italy (Table 1).
These differences may indicate cultural or social differ-
ences, which could be explored in further research.
These variations in the results between the different
scales indicate that the five scales provide complemen-
tary information. Thus, we elected not to calculate a glo-
bal score, as the five individual scores provide a more
complete picture of the impact of rotavirus gastroenter-
itis than a global score could achieve.
Among the study’s strengths are its laboratory con-
firmation of rotavirus infection using PCR, its assess-
ment of case severity using an objective medical
evaluation (the Vesikari score), and its use of a question-
naire validated by recognised methods (as described in
Additional file 1). Another key strength of the study is its
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applying the same study protocol and design. Participants
in all three countries were assessed using the same psy-
chometrically validated questionnaire containing the same
items, thereby allowing exploration of similarities and dif-
ferences in the impact of rotavirus across the different
countries and providing a broad perspective on the burden
of rotavirus gastroenteritis in Europe.
One limitation of our study is that it was not designed
or powered to compare scores according to demographic
or risk factors. Thus, although the results indicate that the
questionnaire is able to discriminate between different
groups of patients, which is encouraging for the future use
of the questionnaire in further research, the differences
reported here should be interpreted with caution. Another
limitation is that the number of respondents in Italy was
small. The lower response rate in Italy compared with the
other two countries may be due to differences in follow-
up, as not all the participating centres in Italy followed up
parents who had not returned the questionnaire. It was
not possible to determine whether patients enrolled in the
study had a previous history of rotavirus gastroenteritis,
because testing for rotavirus infection was not part of rou-
tine clinical practice when the study was conducted, so we
could not assess whether the quality of life impact varied
between first and subsequent episodes.
Another limitation of our study is that it did not include
a control group of rotavirus-negative patients, as all cases
enrolled in the study tested positive for rotavirus on the
rapid test. The PCR-negative cases in the study were ana-
lysed as a comparison group. However, the comparison
should be interpreted with caution, as the PCR-negative
cases were few (n= 34). A full comparison of the impact of
rotavirus gastroenteritis with that of non-rotavirus gastro-
enteritis would require a different study design with a
rotavirus-negative control group. Our results suggest that
the questionnaire described here would be a suitable in-
strument for such a study.
Our results are broadly consistent with those of other
published studies that have investigated the impact of
rotavirus gastroenteritis on families. In Canada, a pro-
spective study in children aged under 3 years presenting
in outpatient settings with rotavirus gastroenteritis (the
MIRAGE study) found that over half (53.8%) of parents
of children with rotavirus gastroenteritis had to take
time off work as a result of their child’s illness [17]. A
sub-analysis of the same study used the EuroQol 5D
(EQ-5D) to assess the parents’ quality of life, and
reported adverse effects of the child’s rotavirus gastro-
enteritis on the parents’ EQ-5D scores on the dimen-
sions of anxiety/depression, pain/discomfort and usual
activities [18]. These studies are consistent with our
findings of adverse effects of childhood rotavirus gastro-
enteritis on parental worry, distress and impact on dailyactivities. The EQ-5D scale is widely used [19] and can
be converted into utility values using a country-specific
algorithm [20], but it is a generic quality of life instru-
ment rather than a disease-specific measure. A smaller
study of children aged 2–36 months presenting with
rotavirus gastroenteritis at outpatient clinics or emer-
gency rooms in North Carolina, USA, used qualitative
interviews with 17 parents to explore the emotional im-
pact of the child’s illness on the family [21]. The parents
were frightened and worried by the severity of the symp-
toms, and reported that the child’s illness caused loss of
sleep, missed work and difficulty in completing normal
household tasks [21]. Although this study did not at-
tempt to quantify these adverse emotional and practical
effects using a scoring system, the issues reported are
consistent with those addressed by our questionnaire.
In Europe, a study in 25 hospitals and five primary care
centres in Spain found that rotavirus-positive gastroenter-
itis in children aged under 2 years was associated with
more severe parental worry and more disruption to house-
hold tasks than rotavirus-negative gastroenteritis [22]. The
multi-country REVEAL study conducted in Belgium,
France, Germany, Italy, Spain, Sweden and the UK in
2004–2005 found high levels of self-reported parental
stress among parents of children with rotavirus gastro-
enteritis aged under 5 years, with mean stress levels of 4.5
to 8.99 on a visual analogue scale from 1 (no stress) to 10
(extremely stressed) [23]. A large survey conducted in 69
paediatric practices in Germany in 2005–2006 used a
questionnaire developed for the study (the Parental
Appraisal of the Morbidity of Diarrhea in Infants and tod-
dlers [PAMODI]) to assess clinical and behavioural symp-
toms, treatment and parental feelings in 2023 parents of
children aged under 2 years presenting with diarrhoea
[24]. Parents’ feelings were characterised by sympathy and
anxiety for the child, followed by feelings of helplessness,
stress and exhaustion. Over half (53.6%)of parents of chil-
dren with severe gastroenteritis reported restrictions on
their normal daily activities [24]. The validity of the
PAMODI questionnaire was supported by the finding that
clinically more severe disease (measured by a modified
Vesikari score) was associated with a higher perceived dis-
ease burden, but the psychometric properties of the
PAMODI questionnaire were not formally investigated.
Our study builds on the earlier results by using a fully vali-
dated questionnaire specifically designed for use with par-
ents of children experiencing rotavirus gastroenteritis.
Conclusions
The present study demonstrates that childhood rotavirus
gastroenteritis presenting to primary care imposes an im-
portant emotional and practical burden on the parents of
the affected child, causing worry, distress and disruption
to normal daily activities. This adverse impact on parents’
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rotavirus gastroenteritis. Prevention of this disease
through prophylactic vaccination will improve the daily
lives not just of the children, but of their families.
Additional file
Additional file 1: Questionnaire validation. Details of the validation of
the questionnaire in PDF format.
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